Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 7/20 | 0.40 |
| ▸ | RAB9A | P51151 | 7/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2285933 | 0.90 | NPC1 (0.45) | MAPTSMN1; SMN2GAAMAPK1TP53 | |
| SCHEMBL2291938 | 0.88 | MAPT (0.38) | MAPTSMN1; SMN2GAAMAPK1KMT2A | |
| SCHEMBL17962528 | 0.83 | PTGS1 (0.50) | MAPTSMN1; SMN2GAAKMT2AHTT | |
| SCHEMBL2295454 | 0.79 | MAP3K5 (0.45) | MAPTSMN1; SMN2GAATP53 | |
| SCHEMBL1495230 | 0.77 | RAB9A (0.53) | MAPTSMN1; SMN2MAPK1KMT2ANPSR1 | |
| SCHEMBL758877 | 0.76 | PTGS1 (0.47) | MAPTSMN1; SMN2GAAMAPK1KMT2A | |
| SCHEMBL2291165 | 0.74 | MAPT (0.41) | MAPTSMN1; SMN2GAAMAPK1KMT2A | |
| SCHEMBL750741 | 0.73 | RAB9A (0.36) | MAPTSMN1; SMN2KMT2AHTTL3MBTL1 | |
| SCHEMBL11989037 | 0.72 | PTGS1 (0.44) | MAPTSMN1; SMN2TP53KDM4EPTGS1 | |
| SCHEMBL913680 | 0.71 | PTGS1 (0.58) | MAPTSMN1; SMN2MAPK1KDM4EPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258151-B2 | 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors | MERCK PATENT GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| US-20110195991-A1 | 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195991-A1 | 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS | GLP1R, SLC5A1, SLC5A2 | MAPT 1138/4885SMN1; SMN2 3644/4885GAA 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.